Pholcodine-induced Stevens-Johnson syndrome in a patient with COVID-19

Vedrana Bulat,1 Robert Likic,2 Nives Pondeljak,1, Marija Delas Azdajic1

Stevens-Johnson syndrome (SJS) is a hypersensitivity reaction with a distinctive clinical pattern characterised by targetoid skin lesions and lesions of at least two anatomic mucosal membranes sites. It is usually triggered by certain drugs, for example, allopurinol, antibiotics (mostly sulfonamides), nonsteroidal anti-inflammatory drugs and aromatic anticonvulsants.1

Most patients show evidence of SJS 7 to 21 days after the first drug exposure.1 Viral infections such as COVID-19 might also induce SJS.2 3 Drug eruptions are often clinically indistinguishable from viral infections.4

We present the case of drug-induced Stevens-Johnson syndrome in a patient with COVID-19. A 23-year-old Caucasian female patient was admitted to our hospital due to oral and genital erosions accompanied by erythematous macules with central dusky violaceous region on her thorax, face, lower extremities, palms and soles.

Prior to development of skin lesions, the patient reported symptoms of high fever, pronounced malaise and headache, which were treated symptomatically. Accordingly, a nasopharyngeal swab was obtained and SARS-CoV-2 reverse transcription PCR (RT-PCR) test came back positive. After a prodromal period, she developed a dry cough. The patient was tested for influenza A virus, adenovirus and rotavirus, all of which were negative, indicating that there were no additional infections at the time of the SARS-CoV-2 infection. X-ray images were unremarkable and pholcodine, an opioid cough suppressant, was prescribed. The patient was taking this medication for 11 days. Three days after discontinuation of pholcodine therapy, she reported erosive lesions in the oral cavity with dysphagia and burning sensation. At that time and in the past 21 days, no other treatments were prescribed or bought over the counter for the management of the SARS-CoV-2 infection. Personal and family history for autoimmune and allergic diseases were negative. Oral lesions were accompanied by haemorrhagic crusting of the lips (figure 1A). Concomitantly with the appearance of oral lesions, the patient noticed a rapid development of symmetrical distribution, round, erythematous macules with central dusky violaceous region on her thorax, which rapidly spread and conflated on the face, genital area, lower extremities, palms and soles (figure 1B). Genital area lesions led to painful micturition. On admission, excisional biopsy of the affected skin was performed. Focal liquefaction degeneration of epidermal keratinocytes and exocytosis of mononuclear cells and eosinophils in the epidermis were seen (figure 1C,D). Therefore, the diagnosis of SJS was based on clinicopathologic correlation. Marked eosinophilia was detected in full blood count that favoured a diagnosis of drug reaction rather than skin lesions induced by viral infection. Parasitic infestations (ectoparasites and helminties), lymphoma, vasculitides (polyarteritis nodosa and Churg-Strauss vasculitis), dermatitis herpetiformis and hepatic cirrhosis were excluded by laboratory and histological findings. Indirect basophil degranulation test was positive. Total IgE and specific IgE to pholcodine were negative due to non-IgE-mediated SJS (performed using ImmunoCAP). Low-dose systemic corticosteroids combined with non-sedating antihistamines were used in order to manage the hyperactivity of the immune system in COVID-19 as well as to control SJS. Skin lesions and lesions of oral and genital mucosa healed without scarring 10 days after discontinuation of pholcodine therapy.

In conclusion, skin and mucosal susceptibility to drugs may be increased in patients with COVID-19. It is possible that the risk of developing SJS is significantly increased in that category of patients as they might have a lowered capacity to detoxify reactive intermediate drug metabolites. Also, SARS-CoV-2 infection could destabilise mastocytes’ membranes in some way, making them more susceptible to degranulation. Finally, drug hypersensitivity syndrome should always be ruled out and all skin changes in patients-COVID-19 ought to be investigated with care.

Contributors All authors have made equal contributions to the article.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID IDs
Robert Likic http://orcid.org/0000-0003-1413-4862
Nives Pondeljak http://orcid.org/0000-0002-3568-1702

REFERENCES